July 2024 - Page 2 of 7 - NetworkNewsWire

FridayJul 26, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Discusses Important Developments of CNM-Au8(R) and Its Novel Technology During Xtalks Podcast

Clene's mission is to transform the treatment of neurodegenerative diseases with a new class of drugs, potentially impacting the lives of millions The company’s uniquely structured gold nanocrystals have the remarkable ability to convert critical energetic metabolites in living cells for the production of ATP, the essential energy currency for cellular functions, offering disease combatting capabilities Clene is currently preparing for Phase 3 clinical trials of CNM-Au8for ALS and MS, following successful early studies Xtalks Life Science Podcast recently featured Karen S. Ho, PhD, Vice President of Translational Medicine for Clene (NASDAQ: CLNN), a late-stage biopharmaceutical company focused on protecting…

ThursdayJul 25, 2024 9:45 am

Nightfood Holdings Inc. (NGTF) Eyes Growth with CarryOut Acquisition

Nightfood made its name in the sleep-friendly snack market, but has made two acquisitions diversifying operations recently to capitalize on an emerging market and a reemerging company Nightfood signed an LOI to acquire SWC Group, d/b/a Carryoutsupplies.com Carryoutsupplies.com has serviced over 7,000 wholesale accounts since inception in 2004, but faced extreme challenges in the face of the global covid pandemic Business is returning, presenting an opportunity for Nightfood to grow sales that reached $2 million in 2023 Nightfood Holdings (OTCQB: NGTF) is at it again. The Tarrytown, NY-based company built its name with sleep-friendly snacks and is now starting to…

ThursdayJul 25, 2024 9:00 am

PaxMedica Inc. (NASDAQ: PXMD) Developing Treatments for Underserved Neurological Disorders

PaxMedica is preparing to submit a New Drug Application to the U.S. Food and Drug Administration for suramin to treat Human African Trypanosomiasis On June 27th, PaxMedica will have a Type C meeting with the FDA, pivotal for the progress of PAX-101, their leading drug candidate for autism treatment, within the regulatory framework The outcomes of this FDA meeting are crucial, representing a key moment for PaxMedica to demonstrate the therapeutic potential and public health benefits of PAX-101 The global ASD therapeutics market is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, driven by increasing…

WednesdayJul 24, 2024 9:45 am

SenesTech Inc.’s (NASDAQ: SNES) Evolve(TM) – Offering Sustainable and Humane Solution to NYC’s Rat Problem

New York City has received lots of backlash, mainly from People for the Ethical Treatment of Animals (“PETA”), for its approach to addressing its rat problem Its approach, so far, has been characterized by the use of traps, poisons, and its “Trash Revolution” program, all of which have been unsustainable SenesTech, a rodent fertility control product provider, through its flagship Evolve(TM) product, offers an alternative that could potentially eliminate the entire rodent population in 12 to 18 months This solution avoids the adverse effects of the use of poisons, both to humans and other animals, and offers a sustainable, more…

WednesdayJul 24, 2024 9:00 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a high unmet medical need Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality of life, making it…

TuesdayJul 23, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members

The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), is thrilled to welcome four seasoned professionals to its executive team. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, said the company was delighted to have this strong group of individuals join…

TuesdayJul 23, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at Emerging Growth Conference 73 – Biotech Feature

CNM-Au8(R) works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health Clene has conducted several clinical trials to evaluate the safety and efficacy of CNM-Au8 in neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) The global ALS treatment market is expected to grow significantly, driven by the increasing prevalence of the disease among the aging population Clene has submitted a briefing book to the FDA to seek feedback on a potential pathway for accelerated approval for CNM-Au8 to treat ALS Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative…

MondayJul 22, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing

Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2 The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug For Lexaria, the results from this study look to validate earlier studies that have demonstrated improvements in the delivery of semaglutide into the bloodstream Results from the GLP-1-H24-2 study are set to be announced in late August or early September Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the dosing completion of its human pilot study #2, GLP-1-H24-2.…

MondayJul 22, 2024 9:45 am

ECGI Holdings Inc. (ECGI) Makes ‘Bold Step Forward’ with Appointment of AI and ML Expert to Board of Advisors

ECGI Holdings, a diversified holding company with a unique portfolio encompassing viticulture, luxury fashion, and hospitality, recently appointed Mandeep Singh, an AI and machine learning expert, to its Board of Advisors Singh’s addition is part of the company’s preparations for the launch of a new line of apparel under Pacific Saddlery’s Allon brand AI provides confidence in size selection, minimizing returns, and better measurement for options, supporting easier upsells Singh will help Pacific Saddlery evaluate and implement technologies to leverage AI precise body measurement solutions to provide personalized fit recommendations In addition, Singh is expected to leverage his experience to…

MondayJul 22, 2024 9:00 am

D-Wave Quantum Inc. (NYSE: QBTS) Adds Second Annealing Quantum Computer in the U.S. and Unveils New Hybrid Quantum Solver

D-Wave introduced its new hybrid quantum solver designed to tackle previously intractable workforce, manufacturing, and logistics optimization problems at its Qubits 2024 conference The new hybrid solver is expected to have a positive impact on a variety of business processes, particularly in workforce, manufacturing, and logistics optimization D-Wave is also deploying a second U.S.-based Advantage(TM) quantum computer at Davidson Technologies’ global headquarters, accessible to D-Wave customers in select countries via D-Wave’s Leap(TM) quantum cloud service D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, continues to make strides in the development and deployment of quantum computing…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Month: July 2024